A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

NCT02220842 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

96

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma

Interventions

DRUG: Atezolizumab
DRUG: Obinutuzumab
DRUG: Tazemetostat

Sponsor

Hoffmann-La Roche